GO:0008173 RNA methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008173 RNA methyltransferase activity describes the catalysis of methyl group transfer from a donor to a nucleoside residue within an RNA molecule.
• This activity is central to epitranscriptomic regulation, generating modifications such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C) that influence RNA stability, translation, and splicing.
• METTL3 and METTL14 form the core m6A methyltransferase complex, where METTL3 provides the catalytic activity and METTL14 supports RNA binding and complex integrity.
• Dysregulated RNA methyltransferase activity is implicated in cancer, cardiovascular disease, and immune evasion, making it a high-value therapeutic target.
• Programmable RNA methyltransferases, such as Cas13-directed METTL3, enable targeted m6A editing for functional studies.
• Robust in vitro and antibody-free assays are available to measure RNA methyltransferase activity for drug discovery and mechanistic research.
Description
RNA methyltransferase activity (GO:0008173) is a fundamental molecular function that transfers a methyl group from a donor molecule, typically S-adenosylmethionine (SAM), to a nucleoside residue within an RNA substrate. This activity generates a diverse array of RNA modifications that collectively constitute the epitranscriptome, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), and 2'-O-methylation. Because these modifications alter RNA structure, stability, localization, and translation, RNA methyltransferases are central regulators of gene expression. Researchers study GO:0008173 to understand how cells control RNA fate and to develop therapies targeting epitranscriptomic enzymes in cancer, cardiovascular disease, and infectious disease. The catalytic mechanisms and biological roles of these enzymes are conserved across eukaryotes and viruses, making them tractable experimental targets.
RNA methyltransferase activity At A Glance
| GO ID | GO:0008173 |
|---|---|
| GO term | RNA methyltransferase activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Catalysis of methyl group transfer to a nucleoside residue in RNA |
| Methyl donor | Typically S-adenosylmethionine (SAM) |
| RNA substrates | mRNA, tRNA, rRNA, lncRNA, viral RNA |
| Major modifications | m6A, m5C, 2'-O-methylation |
| Representative enzymes | METTL3, METTL14, NSUN5, dengue virus NS5 |
What Is GO:0008173?
GO:0008173 RNA methyltransferase activity is defined as the catalysis of methyl group transfer from a donor to a nucleoside residue in an RNA molecule. This activity modifies the RNA base or ribose sugar, producing methylated nucleosides that can affect RNA-protein interactions, secondary structure, and metabolic stability. The reaction typically uses S-adenosylmethionine as the methyl donor, although other donors may exist in specialized contexts.
Why Is RNA methyltransferase activity Important in Cell Biology?
RNA methyltransferase activity is essential for post-transcriptional gene regulation and is dysregulated in numerous human diseases, including cancer, diabetic cardiomyopathy, and viral infections. Because these enzymes write reversible marks on RNA, they offer druggable nodes for therapeutic intervention and are actively pursued as targets in oncology and immunology.
• Controls RNA stability, splicing, export, and translation through m6A and m5C marks.
• Regulates stem cell differentiation and tissue development via epitranscriptomic reprogramming.
• Promotes oncogene translation and cancer cell survival in leukemia and solid tumors.
• Mediates immune evasion in glioma through NSUN5/TET2-dependent RNA modification.
• Is required for exercise-induced benefits in diabetic cardiomyopathy via METTL3.
• Serves as a target for antiviral development, e.g., dengue virus methyltransferase inhibitors.
• Enables programmable RNA editing when fused to Cas13 for targeted m6A deposition.
• Provides biomarkers and therapeutic targets across oncology and cardiovascular disease.
What Happens During RNA methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first finds and grabs the RNA it needs to modify.
RNA methyltransferases recognize specific sequence or structural motifs in target RNAs, often guided by accessory proteins or adaptor complexes. For m6A deposition, METTL3-METTL14 binds consensus DRACH motifs in mRNA, with METTL14 contributing to RNA binding and METTL3 providing catalysis.
Methyl group transfer
In simple terms: The enzyme moves a methyl group onto the RNA base.
The catalytic domain of the enzyme positions S-adenosylmethionine (SAM) and the target nucleoside for methyl transfer, producing S-adenosylhomocysteine (SAH) and methylated RNA. In m6A writers, METTL3 catalyzes the transfer to the N6 position of adenosine.
Product release and RNA fate
In simple terms: After modification, the RNA is released and its behavior changes.
Methylated RNA is released and can be recognized by reader proteins that dictate stability, translation, or decay. For example, m6A marks enhance translation in cancer cells through reader-dependent mechanisms.
Coupling to downstream chromatin and immune signaling
In simple terms: RNA methylation can send signals that affect DNA regulation and immune responses.
NSUN5-mediated m5C on chromatin-associated RNA is converted to 5-hydroxymethylcytosine by TET2, influencing chromatin state and immune evasion in glioma. This illustrates how RNA methyltransferase activity can feed into broader nuclear and immune programs.
Key Genes Involved in GO:0008173 RNA methyltransferase activity
The following genes encode enzymes, cofactors, and regulatory proteins directly implicated in RNA methyltransferase activity (GO:0008173).
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | Catalytic subunit of m6A methyltransferase complex | Cancer translation, diabetic cardiomyopathy, programmable editing |
| METTL14 | RNA-binding scaffold in m6A complex; chromatin regulation | m6A-independent chromatin roles, cancer |
| WTAP | Adaptor protein for m6A complex localization | Splicing and stability regulation |
| NSUN5 | m5C RNA methyltransferase | Glioma immune evasion via TET2 |
| TET2 | Oxidizes m5C to 5hmC on chromatin-associated RNA | Epigenetic crosstalk in glioma |
| NSUN2 | tRNA and mRNA m5C methyltransferase | Translation control, cancer |
| DNMT2 | tRNA m5C methyltransferase | Stress response, translation fidelity |
| FTO | m6A demethylase (eraser) | Obesity, cancer, RNA stability |
| ALKBH5 | m6A demethylase | Spermatogenesis, cancer stemness |
| YTHDF1 | m6A reader | Translation enhancement |
| YTHDF2 | m6A reader | mRNA decay |
| IGF2BP1 | m6A reader | mRNA stabilization in cancer |
| Dengue NS5 | Viral RNA methyltransferase | Antiviral target |
| SARS-CoV-2 nsp14 | Viral RNA methyltransferase | Antiviral target |
| METTL16 | m6A writer for U6 snRNA and MAT2A | Splicing and SAM homeostasis |
| ZC3H13 | m6A complex component | Nuclear m6A deposition |
| RBM15 | m6A complex recruiter | Xist-mediated silencing |
| VIRMA | m6A complex component | 3' UTR m6A deposition |
How Is RNA methyltransferase activity Regulated?
RNA methyltransferase activity is regulated at multiple levels, including enzyme expression, post-translational modification, and interaction with adaptor proteins that dictate substrate specificity. For example, METTL3 activity can be modulated by its interaction with METTL14 and other complex components, and its localization is controlled by WTAP and other adaptors. Additionally, demethylases such as FTO and ALKBH5 dynamically reverse m6A marks, creating a reversible epitranscriptomic switch. In disease contexts, signaling pathways such as those activated by exercise or immune stress can alter methyltransferase expression and activity.
RNA methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Cancer, diabetic cardiomyopathy | KO and overexpression in cancer cell lines and cardiomyocytes |
| METTL14 | Cancer, chromatin regulation | KO and point-mutant knock-in in leukemia cells |
| NSUN5 | Glioma immune evasion | KO and overexpression in glioma cells with TET2 readout |
| Dengue NS5 | Dengue viral infection | In vitro methyltransferase assays and antiviral screening |
| FTO | Obesity, cancer | Overexpression and inhibitor studies in metabolic cell models |
Cancer and epitranscriptomic dysregulation
RNA methyltransferase activity is frequently dysregulated in cancer, where m6A writers such as METTL3 promote translation of oncogenes and sustain tumor growth. METTL14 has been shown to have chromatin regulatory functions independent of its m6A methyltransferase activity, expanding its role in cancer biology. In glioma, NSUN5-mediated m5C modification of chromatin-associated RNA and its conversion by TET2 govern immune evasion, linking RNA methylation to tumor immunology.
Cardiovascular disease and metabolic stress
METTL3 is essential for exercise-induced benefits in diabetic cardiomyopathy, indicating that RNA methyltransferase activity participates in metabolic and cardiovascular homeostasis. This suggests that targeting m6A writing enzymes could have therapeutic potential in heart disease.
Viral infection and antiviral targeting
Many viruses encode their own RNA methyltransferases, such as dengue virus NS5, which are required for viral RNA capping and immune evasion. Inhibiting these enzymes with RNA aptamers or small molecules represents a promising antiviral strategy.
From RNA methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of m6A writing affect translation? | METTL3 knockout cell lines with Ribo-seq |
| Is the catalytic activity required for function? | Catalytically dead METTL3 point mutant (e.g., D395A) knock-in |
| How does m5C on chromatin RNA affect immunity? | NSUN5 knockout and TET2 knockout glioma models |
| Can we target viral methyltransferase? | Dengue NS5 overexpression and aptamer inhibition assays |
| What is the role of METTL3 in heart disease? | Cardiomyocyte-specific METTL3 knockout mice |
| Can we program m6A at specific sites? | Cas13-METTL3 fusion overexpression in cells |
How to Study the RNA methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro methyltransferase assay | Enzymatic activity using SAM donor | Enzyme kinetics and inhibitor screening |
| Antibody-free activity assay | Methyltransferase activity without antibodies | High-throughput drug discovery |
| m6A-seq / MeRIP-seq | Transcriptome-wide m6A sites | Mapping methylation targets |
| Bisulfite sequencing | m5C sites at single-base resolution | Mapping NSUN5 targets |
| Ribo-seq | Translation efficiency | Functional impact of m6A on translation |
| Cas13-METTL3 editing | Site-specific m6A deposition | Programmable epitranscriptome editing |
| RNA aptamer inhibition | Enzyme inhibition by aptamers | Antiviral development |
| Western blot / qPCR | Protein and RNA expression | Validating knockout and overexpression |
In vitro methyltransferase activity assays
Recombinant enzymes can be incubated with RNA substrates and radiolabeled or fluorescent SAM to measure methyl transfer directly. Antibody-free assays have been developed to quantify RNA methyltransferase activity in a high-throughput format.
RNA modification mapping
Techniques such as m6A-seq, MeRIP-seq, and bisulfite sequencing for m5C allow transcriptome-wide mapping of methylation marks deposited by these enzymes.
Ribosome profiling and translation analysis
Ribo-seq measures translation efficiency and has been used to show that METTL3 promotes translation in cancer cells.
Programmable editing and imaging
Cas13-directed methyltransferases enable site-specific m6A deposition, allowing functional dissection of individual marks. Fluorescent labeling of RNA and enzymes can reveal localization dynamics.
How CRISPR Can Be Used to Study GO:0008173 RNA methyltransferase activity
Knockout
CRISPR knockout of METTL3 or METTL14 abolishes m6A deposition and has been used to demonstrate their roles in translation and chromatin regulation. Knockout models are essential for distinguishing catalytic from non-catalytic functions.
Point Mutation
Catalytically dead point mutants, such as METTL3 D395A, allow researchers to separate methyltransferase activity from scaffolding functions. Such mutants are valuable for dissecting m6A-dependent and independent roles.
Knock-in
Knock-in of tagged or mutant enzymes enables precise tracking and functional analysis of RNA methyltransferases in their native genomic context. This approach is useful for studying localization and interactomes.
Overexpression
Overexpression of wild-type or fusion enzymes, such as Cas13-METTL3, allows gain-of-function studies and programmable editing of specific RNA sites. Overexpression models are widely used to study oncogenic roles of METTL3.
How EDITGENE Supports RNA methyltransferase activity Research
Researchers studying RNA methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific RNA modification or disease phenotype. This requires precise genetic models that can isolate catalytic activity, localization, and interaction partners.
Contact EDITGENE today to design your custom CRISPR model for RNA methyltransferase activity research.
Frequently Asked Questions About RNA methyltransferase activity
What is RNA methyltransferase activity?
RNA methyltransferase activity (GO:0008173) is the catalysis of methyl group transfer from a donor to a nucleoside residue in an RNA molecule, generating modifications such as m6A and m5C.
What genes are involved in RNA methyltransferase activity?
Key genes include METTL3, METTL14, WTAP, NSUN5, TET2, and viral enzymes such as dengue NS5.
How is RNA methyltransferase activity measured?
It can be measured using in vitro methyltransferase assays with SAM donors, antibody-free activity assays, and RNA modification mapping techniques.
What diseases are linked to RNA methyltransferase activity?
Dysregulation is linked to cancer, diabetic cardiomyopathy, glioma immune evasion, and viral infections.
What is the role of METTL3 in cancer?
METTL3 promotes translation of oncogenes and cancer cell survival through m6A deposition.
Can RNA methyltransferase activity be targeted therapeutically?
Yes, inhibitors and RNA aptamers targeting viral and human methyltransferases are under investigation.
What is the difference between m6A and m5C?
m6A is methylation of adenosine and is deposited by METTL3-METTL14, while m5C is methylation of cytosine and is deposited by NSUN family enzymes.
How does METTL14 function independently of m6A?
METTL14 can regulate chromatin and gene expression independently of its methyltransferase activity, as shown by knockout and mutant studies.
What is Cas13-directed m6A editing?
It is a programmable system that fuses Cas13 with a methyltransferase to deposit m6A at specific RNA sites.
What CRISPR models are used to study RNA methyltransferases?
Knockout, point-mutant knock-in, tagged knock-in, and overexpression models are commonly used to dissect function.
Conclusion
RNA methyltransferase activity (GO:0008173) is a central molecular function that shapes the epitranscriptome and influences diverse biological processes, from translation to immune evasion. Its dysregulation contributes to cancer, cardiovascular disease, and viral pathogenesis, making it a compelling target for therapeutic development. Advances in CRISPR modeling, programmable editing, and high-throughput assays continue to accelerate mechanistic and translational research in this field.
References
- 1. Dou X et al.. 2023. METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity.. Protein Cell 14(9):683-697 PMID: 37030005
- 2. Shelton SB et al.. 2019. Antibody-Free Assay for RNA Methyltransferase Activity Analysis.. J Vis Exp PMID: 31355783
- 3. Haag S et al.. 2017. In Vitro Assays for RNA Methyltransferase Activity.. Methods Mol Biol 1562:259-268 PMID: 28349466
- 4. Wilson C et al.. 2020. Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase.. Nat Biotechnol 38(12):1431-1440 PMID: 32601430
- 5. Wu R et al.. 2024. NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion.. Proc Natl Acad Sci U S A 121(14):e2321611121 PMID: 38547058
- 6. Wang C et al.. 2025. METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.. Circulation 152(5):327-345 PMID: 40357551
- 7. Jung JI et al.. 2018. Development of RNA aptamer that inhibits methyltransferase activity of dengue virus.. Biotechnol Lett 40(2):315-324 PMID: 29063288
- 8. Lin S et al.. 2016. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.. Mol Cell 62(3):335-345 PMID: 27117702
